NO20015481L - Nye indikasjoner på mannanbindende lectin (MBL) ved behandlingen av immunkompromitterte individer - Google Patents

Nye indikasjoner på mannanbindende lectin (MBL) ved behandlingen av immunkompromitterte individer

Info

Publication number
NO20015481L
NO20015481L NO20015481A NO20015481A NO20015481L NO 20015481 L NO20015481 L NO 20015481L NO 20015481 A NO20015481 A NO 20015481A NO 20015481 A NO20015481 A NO 20015481A NO 20015481 L NO20015481 L NO 20015481L
Authority
NO
Norway
Prior art keywords
treatment
mbl
mannan
prophylaxis
binding lectin
Prior art date
Application number
NO20015481A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015481D0 (no
Inventor
Steffen Thiel
Jens Christian Jensenius
Original Assignee
Jens Christian Jensenius
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jens Christian Jensenius filed Critical Jens Christian Jensenius
Publication of NO20015481D0 publication Critical patent/NO20015481D0/no
Publication of NO20015481L publication Critical patent/NO20015481L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Filtering Materials (AREA)
  • Wrappers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
NO20015481A 1999-05-14 2001-11-08 Nye indikasjoner på mannanbindende lectin (MBL) ved behandlingen av immunkompromitterte individer NO20015481L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900668 1999-05-14
DKPA199901508 1999-10-20
PCT/DK2000/000247 WO2000069894A2 (en) 1999-05-14 2000-05-10 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals

Publications (2)

Publication Number Publication Date
NO20015481D0 NO20015481D0 (no) 2001-11-08
NO20015481L true NO20015481L (no) 2002-01-11

Family

ID=26064419

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20015481A NO20015481L (no) 1999-05-14 2001-11-08 Nye indikasjoner på mannanbindende lectin (MBL) ved behandlingen av immunkompromitterte individer
NO20015506A NO20015506L (no) 1999-05-14 2001-11-09 Rekombinant humant mannanbindende lectin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20015506A NO20015506L (no) 1999-05-14 2001-11-09 Rekombinant humant mannanbindende lectin

Country Status (15)

Country Link
US (5) US6562784B1 (de)
EP (3) EP1181038B1 (de)
JP (2) JP2002544286A (de)
CN (2) CN1359298A (de)
AT (3) ATE336260T1 (de)
AU (2) AU779404B2 (de)
CA (2) CA2372435A1 (de)
DE (3) DE60033147T2 (de)
DK (3) DK1402897T3 (de)
ES (3) ES2281341T3 (de)
NO (2) NO20015481L (de)
NZ (2) NZ515717A (de)
PT (3) PT1181363E (de)
RU (2) RU2292217C2 (de)
WO (2) WO2000069894A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
ES2281341T3 (es) * 1999-05-14 2007-10-01 Steffen Thiel Lectina humana recombinante que se une a manano.
WO2002005833A1 (en) * 2000-07-13 2002-01-24 Natimmune A/S MANNAN-BINDING LECTIN (MBL) TREATMENT OF INFECTIONS IN INDIVIDUALS TREATED WITH TNF-αinhibitors
EP1186299A1 (de) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnose, Verbeugung und/oder Behandlung von Atherosklerose, Infectionen und Störungen des Immunsystems
US20040043034A1 (en) * 2000-11-27 2004-03-04 Jensenius Jens Christian Collectins as adjuvants
WO2003010188A1 (en) 2001-07-23 2003-02-06 Natimmune A/S Production of high molecular mass lectins
JP4051030B2 (ja) * 2001-08-31 2008-02-20 扶桑薬品工業株式会社 ヒトマンノース結合レクチンの精製方法、ヒトマンノース結合レクチン組成物およびヒトマンノース結合レクチンの医薬用途
EP1335932B1 (de) * 2001-10-19 2005-11-30 Natimmune A/S Isolierung von lectinen
CN1652813A (zh) * 2002-03-15 2005-08-10 纳蒂芒公司 包含甘露糖结合凝集素的药用组合物
US7211396B2 (en) 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin
JP2005523336A (ja) * 2002-04-24 2005-08-04 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ マンノース結合レクチン及びその使用方法
US20050123899A1 (en) * 2002-06-28 2005-06-09 Nobutaka Wakamiya Anti-hiv agent
DK1539964T3 (da) * 2002-09-10 2007-05-07 Natimmune As Cellectin-komplementaktiverende proteinkimærer
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
CA2516403C (en) * 2003-01-17 2014-08-12 Aethlon Medical, Inc. Method for removal of viruses from blood by lectin affinity hemodialysis
PT2374819T (pt) 2003-05-12 2017-07-04 Helion Biotech Aps Anticorpos para masp-2
US7135338B2 (en) * 2003-06-11 2006-11-14 Dobeel Corporation Methods for overexpression of high molecular weight form of mannose binding lectin (MBL) and a specific formulation for active treatment for systemic infection with microorganism
DE20317914U1 (de) 2003-11-19 2004-12-30 Weh, Erwin Betätigungsvorrichtung für eine Schnellanschlusskupplung
US7335633B2 (en) 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
WO2005080594A2 (en) * 2004-02-24 2005-09-01 Innogenetics N.V. Method for determining the risk of developing a neurological disease
US7964559B2 (en) 2004-03-09 2011-06-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services MVL, an antiviral protein from a cyanobacterium
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1618887A1 (de) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Beseitigung von Polyolen aus dem Körper
EP1797197A1 (de) * 2004-09-29 2007-06-20 Mellitus S.L. Verfahren zur detektion einer prädisposition für schwangerschaftsdiabetes sowie zur behandlung dieser krankheit
DE602005026705D1 (de) * 2004-12-23 2011-04-14 Council Scient Ind Res Pharmazeutische zusammensetzung zur behandlung von invasiver lungenaspergillose
CN101094651B (zh) * 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
CN101193651A (zh) * 2005-04-11 2008-06-04 内蒂穆恩公司 甘露聚糖结合凝集素(mbl)在治疗与癌症相关的免疫削弱的病症中的用途
US9220831B2 (en) 2005-10-06 2015-12-29 Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
WO2007085057A1 (en) * 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
US20070226567A1 (en) * 2006-03-23 2007-09-27 Gorman Kevin W High speed bist utilizing clock multiplication
US20110052428A1 (en) * 2008-01-16 2011-03-03 Superpar Otomotiv Sanayi Ve Ticaret Anonim Sirketi Electric fuel pump for heavy duty engine platforms
US20100331240A1 (en) * 2008-01-18 2010-12-30 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins
WO2010123594A2 (en) 2009-01-15 2010-10-28 Children's Medical Center Corporation Device for filtration of fluids there through and accompanying method
DK2526119T3 (en) * 2010-01-19 2018-07-30 Harvard College Manipulated opsonin for pathogen detection and treatment
WO2011100528A2 (en) * 2010-02-12 2011-08-18 Emory University Compositions and uses of lectins
DE102011003478A1 (de) * 2011-02-01 2012-08-02 Cytavis Biopharma Gmbh Antivirales Mittel enthaltend rekombinante Mistellektine
CA2842321C (en) 2011-07-18 2022-05-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
AU2013225823A1 (en) 2012-02-29 2014-09-18 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
US20150173883A1 (en) 2012-07-18 2015-06-25 President And Fellows Of Harvard College Modification of surfaces for simultaneous repellency and targeted binding of desired moieties
EP2976642A4 (de) 2013-03-15 2016-09-21 Harvard College Verfahren und zusammensetzungen zur verbesserung der erkennung und/oder aufnahme einer zieleinheit
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3083658B1 (de) 2013-12-18 2019-05-08 President and Fellows of Harvard College Detektion gram-positiver bakterien mit crp
WO2016077067A2 (en) * 2014-10-27 2016-05-19 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
EP3331549B1 (de) 2015-08-06 2020-12-23 President and Fellows of Harvard College Verbesserte mikrobenbindende moleküle und verwendungen davon
EP3458483A1 (de) 2016-05-16 2019-03-27 President and Fellows of Harvard College Wässriges biomolekül mit kopplung an co2-plasma-aktivierte oberflächen
CN107050427A (zh) * 2017-02-27 2017-08-18 新乡医学院 MBL在制备预防或治疗以Tregs为靶点的疾病药物中的应用
CN107050436B (zh) * 2017-02-27 2020-03-17 新乡医学院 Mbl在制备预防或治疗效应t细胞引发疾病药物中的应用
WO2019110706A1 (en) * 2017-12-08 2019-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of developing a sepsis or a systemic inflammatory response syndrome (sirs)
RU2739113C1 (ru) * 2019-10-04 2020-12-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр терапии и профилактической медицины" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТПМ" Минздрава России) Способ определения активности маннан-связывающих лектин-ассоциированных сериновых протеаз в тесте коагуляции фибриногена
WO2023087090A1 (en) * 2021-11-18 2023-05-25 Magellan Therapeutics Inc. Recombinant proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001519A1 (en) * 1987-08-20 1989-02-23 Children's Hospital Corporation Human mannose binding protein
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
US5112952A (en) 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
EP0856580A4 (de) 1995-08-17 2001-02-07 Fuso Pharmaceutical Ind Rekombinantes conglutinin und verfahren zu dessen herstellung
AU8748198A (en) 1997-08-21 1999-03-16 Takara Shuzo Co., Ltd. Carcinostatic agents
WO1999064453A1 (en) 1998-06-10 1999-12-16 Statens Serum Institut Purification process for production of mannan-binding lectin and an mbl medicinal product
ES2281341T3 (es) * 1999-05-14 2007-10-01 Steffen Thiel Lectina humana recombinante que se une a manano.

Also Published As

Publication number Publication date
US6562784B1 (en) 2003-05-13
NO20015506L (no) 2002-01-09
WO2000070043A1 (en) 2000-11-23
ES2271468T3 (es) 2007-04-16
RU2292217C2 (ru) 2007-01-27
AU4393600A (en) 2000-12-05
AU4393500A (en) 2000-12-05
DE60009896D1 (de) 2004-05-19
US20040229212A1 (en) 2004-11-18
ES2219336T3 (es) 2004-12-01
NZ515717A (en) 2004-01-30
PT1181363E (pt) 2007-05-31
CA2372128A1 (en) 2000-11-23
DE60033147D1 (de) 2007-03-15
CN1359420A (zh) 2002-07-17
DK1181363T3 (da) 2007-05-29
EP1402897B1 (de) 2006-08-16
NO20015506D0 (no) 2001-11-09
JP2002543837A (ja) 2002-12-24
US7202207B2 (en) 2007-04-10
US6846649B1 (en) 2005-01-25
EP1181038B1 (de) 2004-04-14
AU781135B2 (en) 2005-05-05
CA2372435A1 (en) 2000-11-23
WO2000069894A2 (en) 2000-11-23
DK1181038T3 (da) 2004-08-09
WO2000069894A3 (en) 2001-02-08
NZ515718A (en) 2004-03-26
ATE352620T1 (de) 2007-02-15
ES2281341T3 (es) 2007-10-01
DE60030173T2 (de) 2007-08-23
EP1181363B1 (de) 2007-01-24
DE60009896T2 (de) 2005-04-21
AU779404B2 (en) 2005-01-20
DE60033147T2 (de) 2007-12-13
US20070197428A1 (en) 2007-08-23
EP1181038A2 (de) 2002-02-27
RU2005125625A (ru) 2007-02-20
US7439224B2 (en) 2008-10-21
NO20015481D0 (no) 2001-11-08
US20030191052A1 (en) 2003-10-09
EP1402897A3 (de) 2004-06-30
JP2002544286A (ja) 2002-12-24
EP1181363A1 (de) 2002-02-27
CN1359298A (zh) 2002-07-17
EP1402897A2 (de) 2004-03-31
DK1402897T3 (da) 2006-12-27
PT1402897E (pt) 2007-01-31
DE60030173D1 (de) 2006-09-28
ATE264111T1 (de) 2004-04-15
PT1181038E (pt) 2004-08-31
ATE336260T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
NO20015481L (no) Nye indikasjoner på mannanbindende lectin (MBL) ved behandlingen av immunkompromitterte individer
MY106315A (en) Pharmaceutical agents
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
MA27998A1 (fr) Nouvelle formulation
FI961438A0 (fi) beta-amyloidiproteiinituotannon estäjiä
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
DK1455605T3 (da) Læskedrikerstatning
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
HUP9903906A2 (hu) Kelátképző clioquinol felhasználása Alzheimer-kór kezelésére alkalmas gyógyszerkészítmények előállításánál
HUP0103889A2 (hu) Kopolimer-1-rokon polipeptidek alkalmazása molekulatömeg kalibráló standardként és gyógyászati anyagként
BG105302A (en) Means for improving cognition
ATE291424T1 (de) Katechin und quercetin zur pharmazeutischen oder diätetischen verwendung
DE60025026D1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
WO1996022305A3 (en) Modified peptides
ES2162520T3 (es) Medicamentos basados en hiperforina y/o extractos de hiperforina.
AU4568400A (en) Sphingomyelinase inhibitor
WO2002090552A3 (en) Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
HUP0402298A2 (hu) Dezoxipeganin alkalmazása klinikai depresszió kezelésére
FR2710844B1 (fr) Composition pour le traitement ou la prévention de l'herpès.
NZ228068A (en) Brominated or chlorinated allylamines and their pharmaceutical compositions
MXPA02003731A (es) Derivados novedosos de acido fusidico.
FR2823207B1 (fr) Complexes d'anilides a chaine polycarbonee et de cyclodestrines, leur preparation et leur application en tant que medicamment en particulier pour le traitement des dislipidemies
WO2002097075A3 (en) Capping enzyme of flavivirus and utilization of this protein in a process to test drugs with antiviral properties
ES2127133A1 (es) Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.
Scott Focusing on the Efficacy of Tizanidine in the Multiple Sclerosis Clinic